IASLC’s Hot Topic Meetings in Basic and Translational Science serve as a platform to share cutting-edge research, discuss challenges in the field, and explore collaborative opportunities among academic and with industrial researchers to advance the understanding and treatment of non-small cell lung cancer. Attendees will gain insights into the molecular and cellular processes behind treatment tolerance and resistance, as well as explore new therapeutic strategies and translational insights that bridge the gap between basic research and clinical application. The meeting will feature a diverse audience, including scientists, clinicians, pathologists, radiologists, and industry professionals, reflecting the multidisciplinary approach necessary to tackle the complexities of NSCLC.

Live conference Dates: December 13-15, 2024

The target audience includes basic scientists, translational researchers, oncologists, pathologists, molecular biologists, radiologists, pharmaceutical and biotech professionals, academic researchers, students, and more. The multidisciplinary nature of the audience reflects the comprehensive approach required to address the complexities of tolerance and resistance to targeted therapy in non-small cell lung cancer.

Upon completion of this activity, the participants shoudl be able to: 

• Synthesize cutting edge research from clinical trials and translational studies conducted around the world.
• Gain insights into the molecular and cellular processes behind treatment tolerance and resistance.
• Explore new therapeutic strategies and translational insights that bridge the gap between basic research and clinical application.
• Discuss challenges in lung and thoracic cancer research.
• Inspire innovative solutions for the future direction of lung cancer research and treatment.

• Alice Berger, PhD
• William Lockwood, PhD
• Montse Sanchez-Cespedes, PhD
• Kenichi Suda, MD, PhD

The information presented is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities

If you need assistance with this activity, please email: education@iaslc.org.